-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2020, the global demand for the expansion of production lines of biological products such as vaccines has increased sharply, and the overall performance of pharmaceutical equipment companies in the industrial chain has seen substantial growth
.
Pharmaceutical equipment (Source: Pharmaceutical Network) Taking the representative domestic pharmaceutical equipment companies such as Chutian Technology, Tofflon, and Canaan Technology as examples, the public financial report data shows that in the first three quarters of 2020 and 2021 , Chutian Technology achieved revenue of 3.
576 billion yuan and 3.
682 billion yuan respectively, an increase of 13.
88% and 67.
24% year-on-year respectively; net profit was 201 million yuan and 401 million yuan respectively, an increase of 207.
62% and 723.
53% year-on-year respectively
.
In 2020 and 2021, Tofflon achieved revenue of 2.
708 billion yuan and 4.
192 billion yuan respectively, an increase of 19.
60% and 54.
83% year-on-year respectively; net profit was 463 million yuan and 828 million yuan respectively, a year-on-year increase of 217.
86% and 78.
59% respectively.
.
In 2020 and 2021, Canaan Technology achieved revenue of 1.
007 billion yuan and 1.
059 billion yuan respectively, a year-on-year increase of 43.
25% and 5.
20% respectively; net profit was 67.
91 million yuan and 76.
1539 million yuan respectively, a year-on-year increase of 32.
33% and 12.
15% respectively.
.
In addition, Canaan Technology released the first-quarter performance forecast on the evening of March 31, 2022, and it is expected to achieve a net profit of 16.
1357 million yuan to 19.
3628 million yuan in the first quarter of 2022, a year-on-year increase of 50% to 80%
.
Judging from the reasons for the growth of the above-mentioned pharmaceutical machine companies in recent years, the business of biopharmaceutical equipment and consumables is the driving force for the rapid growth of many companies
.
In recent years, with the rise of new fields such as biopharmaceuticals, new therapies such as cell and gene therapy, and the support of favorable policies, the domestic biopharmaceutical industry has broad prospects, bringing considerable growth to the pharmaceutical equipment industry.
With the continuous rise of strength and the accelerated pace of import substitution, the prospects of pharmaceutical equipment are generally optimistic in the industry
.
In order to meet market demand and seize a new round of opportunities, many pharmaceutical machine companies have paid more attention to research and development in recent years, and have been actively producing
.
In terms of R&D, for example, Chutian Technology’s R&D investment continues to rise steadily.
In 2020, there are 1,121 R&D personnel, accounting for 36.
94%; R&D investment is 288 million yuan, accounting for 8.
05% of revenue
.
Tofflon will have 396 R&D personnel in 2020, accounting for 14.
88% of the total; R&D investment is 156 million yuan, accounting for 5.
77% of the company's total revenue
.
In terms of production capacity, for example, on April 20, Tofflon told investors at the performance briefing held that the company currently has sufficient orders and is actively deploying production capacity according to its own development needs
.
It is understood that in February this year, Tofflon issued an announcement announcing that the company planned to raise no more than 3.
2 billion yuan for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, and the Hangzhou life science industrialization project.
Base projects and supplementary working capital
.
In addition, as early as 2020, the company will plan the production capacity, carry out the intelligent equipment manufacturing science and technology innovation industrial park project in Dongtai Xinte Industrial Park, Jiangsu Province, and invest in the construction of biopharmaceutical system equipment industrialization project in Shanghai Jinshan Industrial Zone.
It is reported that, At present, its Jiangsu Dongtai project and Jinshan biopharmaceutical system equipment industrialization project are both under construction
.
Chutian Technology also stated on the interactive platform in mid-March that the company will gradually expand its production capacity according to the actual needs of development
.
It is reported that the capacity expansion covers an area of 142 mu, mainly covering the bioengineering sector, the intelligent after-package workshop, and the intelligent traditional Chinese medicine workshop
.
According to a research report released by GF Securities in March, the company has strong cohesion and execution, and has the advantage of low cost of capacity expansion
.
In the case of abundant market demand, production lines can be quickly deployed to occupy market share
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Pharmaceutical equipment (Source: Pharmaceutical Network) Taking the representative domestic pharmaceutical equipment companies such as Chutian Technology, Tofflon, and Canaan Technology as examples, the public financial report data shows that in the first three quarters of 2020 and 2021 , Chutian Technology achieved revenue of 3.
576 billion yuan and 3.
682 billion yuan respectively, an increase of 13.
88% and 67.
24% year-on-year respectively; net profit was 201 million yuan and 401 million yuan respectively, an increase of 207.
62% and 723.
53% year-on-year respectively
.
In 2020 and 2021, Tofflon achieved revenue of 2.
708 billion yuan and 4.
192 billion yuan respectively, an increase of 19.
60% and 54.
83% year-on-year respectively; net profit was 463 million yuan and 828 million yuan respectively, a year-on-year increase of 217.
86% and 78.
59% respectively.
.
In 2020 and 2021, Canaan Technology achieved revenue of 1.
007 billion yuan and 1.
059 billion yuan respectively, a year-on-year increase of 43.
25% and 5.
20% respectively; net profit was 67.
91 million yuan and 76.
1539 million yuan respectively, a year-on-year increase of 32.
33% and 12.
15% respectively.
.
In addition, Canaan Technology released the first-quarter performance forecast on the evening of March 31, 2022, and it is expected to achieve a net profit of 16.
1357 million yuan to 19.
3628 million yuan in the first quarter of 2022, a year-on-year increase of 50% to 80%
.
Judging from the reasons for the growth of the above-mentioned pharmaceutical machine companies in recent years, the business of biopharmaceutical equipment and consumables is the driving force for the rapid growth of many companies
.
In recent years, with the rise of new fields such as biopharmaceuticals, new therapies such as cell and gene therapy, and the support of favorable policies, the domestic biopharmaceutical industry has broad prospects, bringing considerable growth to the pharmaceutical equipment industry.
With the continuous rise of strength and the accelerated pace of import substitution, the prospects of pharmaceutical equipment are generally optimistic in the industry
.
In order to meet market demand and seize a new round of opportunities, many pharmaceutical machine companies have paid more attention to research and development in recent years, and have been actively producing
.
In terms of R&D, for example, Chutian Technology’s R&D investment continues to rise steadily.
In 2020, there are 1,121 R&D personnel, accounting for 36.
94%; R&D investment is 288 million yuan, accounting for 8.
05% of revenue
.
Tofflon will have 396 R&D personnel in 2020, accounting for 14.
88% of the total; R&D investment is 156 million yuan, accounting for 5.
77% of the company's total revenue
.
In terms of production capacity, for example, on April 20, Tofflon told investors at the performance briefing held that the company currently has sufficient orders and is actively deploying production capacity according to its own development needs
.
It is understood that in February this year, Tofflon issued an announcement announcing that the company planned to raise no more than 3.
2 billion yuan for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, and the Hangzhou life science industrialization project.
Base projects and supplementary working capital
.
In addition, as early as 2020, the company will plan the production capacity, carry out the intelligent equipment manufacturing science and technology innovation industrial park project in Dongtai Xinte Industrial Park, Jiangsu Province, and invest in the construction of biopharmaceutical system equipment industrialization project in Shanghai Jinshan Industrial Zone.
It is reported that, At present, its Jiangsu Dongtai project and Jinshan biopharmaceutical system equipment industrialization project are both under construction
.
Chutian Technology also stated on the interactive platform in mid-March that the company will gradually expand its production capacity according to the actual needs of development
.
It is reported that the capacity expansion covers an area of 142 mu, mainly covering the bioengineering sector, the intelligent after-package workshop, and the intelligent traditional Chinese medicine workshop
.
According to a research report released by GF Securities in March, the company has strong cohesion and execution, and has the advantage of low cost of capacity expansion
.
In the case of abundant market demand, production lines can be quickly deployed to occupy market share
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
